To evaluate if prescribing pancreatic enzymes in patients with pancreatic cancer leads to a decrease in weight loss. every month during 6 months after inclusion [clinicaltrials_resource:54a2005ea67b0c5bf6ede30fd935d3f1]
Percentage of change in body weight ((index weight - monthly weight)/ index weight) x100% during the 6 months of follow-up. This will be measured on a monthly basis and measured by area under the ROC (Receiver Operating Characteristic) curve
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To evaluate if prescribing pancreatic enzymes in patients with pancreatic cancer leads to a decrease in weight loss. every month during 6 months after inclusion [clinicaltrials_resource:54a2005ea67b0c5bf6ede30fd935d3f1]
Percentage of change in body weight ((index weight - monthly weight)/ index weight) x100% during the 6 months of follow-up. This will be measured on a monthly basis and measured by area under the ROC (Receiver Operating Characteristic) curve
Bio2RDF identifier
54a2005ea67b0c5bf6ede30fd935d3f1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:54a2005ea67b0c5bf6ede30fd935d3f1
measure [clinicaltrials_vocabulary:measure]
To evaluate if prescribing pan ...... to a decrease in weight loss.
time frame [clinicaltrials_vocabulary:time-frame]
every month during 6 months after inclusion
description
Percentage of change in body w ...... perating Characteristic) curve
identifier
clinicaltrials_resource:54a2005ea67b0c5bf6ede30fd935d3f1
title
To evaluate if prescribing pan ...... uring 6 months after inclusion
@en
type
label
To evaluate if prescribing pan ...... 2005ea67b0c5bf6ede30fd935d3f1]
@en